Online inquiry

IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5966MR)

This product GTTS-WQ5966MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5966MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8930MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ5235MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ13134MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ6975MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ10849MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ6814MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ9125MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ15203MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW